Key result
Direct factor Xa inhibitors show higher recurrence and bleeding risk in renal impairment with VTE.
Why the study?
Patients with venous thromboembolism and renal impairment are at higher risk for both recurrence and bleeding but are underrepresented in clinical trials, leaving the benefit-risk balance of direct factor Xa inhibitors uncertain in this population.
Population
Patients with venous thromboembolism and renal impairment
Comparison
Direct factor Xa inhibitors vs conventional anticoagulation
Design
Randomized trial
Answers are grounded in this paper and cite their sources.
Renal impairment raises VTE recurrence and bleeding risk on DXI; leaves open optimal dosing in this underrepresented population.
In patients with venous thromboembolism (VTE), renal impairment is a risk factor for both recurrence and bleeding. Because these patients are underrepresented in clinical trials, the benefit–risk balance of direct factor Xa inhibitors (DXI) warrants dedicated assessment in this population.
No takes yet. Share an insight, caveat, or question.
Mismetti et al. (2026) studied this question. Direct factor Xa inhibitors warrant dedicated assessment against conventional anticoagulation in patients with venous thromboembolism and renal impairment due to increased recurrence and bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: